Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease
NPJ Parkinsons Dis
.
2024 Mar 14;10(1):59.
doi: 10.1038/s41531-024-00657-7.
Author
Michel Alexander Steiner
1
Affiliation
1
Idorsia Pharmaceuticals Ltd, CNS Pharmacology, Hegenheimermattweg 91, 4123, Allschwil, Switzerland. michel.steiner@idorsia.com.
PMID:
38486022
PMCID:
PMC10940697
DOI:
10.1038/s41531-024-00657-7
No abstract available
Publication types
Letter